Malaysian Health Ministry Set to Propose Public Health Smoking Control Act 2023

Regulations by 2FIRSTS.ai
Nov.28.2023
Malaysian Health Ministry Set to Propose Public Health Smoking Control Act 2023
Malaysia's Health Ministry plans to introduce the Public Health Control of Smoking Products Act 2023 to regulate harmful tobacco products.

According to a report by TheEdgeMarkets on November 22nd, the Malaysian Ministry of Health is ensuring that the "2023 Public Health Control of Smoking Products Bill" will be presented before the end of the parliamentary session on November 30th. This move aims to address the legal loophole regarding the exclusion of nicotine gel in the 1952 Dangerous Drugs Act.

 

Minister of Health Zaliha Mustafa stated that this legislation aims to comprehensively regulate smoking products that have been scientifically proven to be harmful to one's health.

 

After considering the views of the Attorney General, the Ministry of Health will revise the bill for the proposal in the upcoming cabinet meeting this Friday.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

UK Launches Call for Evidence to Shape New Tobacco and Vapes Regulations
UK Launches Call for Evidence to Shape New Tobacco and Vapes Regulations
The UK's Department of Health and Social Care (DHSC) has launched an eight-week comprehensive call for evidence to inform new regulations under the forthcoming Tobacco and Vapes Bill, with a deadline of December 3, 2025. The initiative aims to systematically gather evidence on vape flavors, ingredients, nicotine levels, and product design, as well as proposals for an omnichannel retail licensing scheme for tobacco and vapes and a new product registration system.
Nov.04 by 2FIRSTS.ai
Product | ELFBAR Launches New Open-System Device in UK with Three Pod Options and 2800mAh Battery
Product | ELFBAR Launches New Open-System Device in UK with Three Pod Options and 2800mAh Battery
ELFBAR has launched its new open-system device ELFX MEGA, compatible with 2 mL, 5 mL and 10 mL pods and equipped with a 2800mAh battery that delivers significantly longer runtime than its predecessor. The device has passed MHRA notification in the UK and is now available online in the UK at a retail price of around £18.99.
Nov.25 by 2FIRSTS.ai
Dagestan Proposes Pilot Ban on E-Cigarette Sales, Submits Request to State Duma
Dagestan Proposes Pilot Ban on E-Cigarette Sales, Submits Request to State Duma
The head of Russia’s Republic of Dagestan has proposed a region-wide ban on the retail sale of e-cigarettes and has written to the State Duma seeking to designate Dagestan as a pilot region for a comprehensive e-cigarette sales ban.
Oct.21 by 2FIRSTS.ai
China Opens 2026 National E-Cigarette Standards Project for Public Submissions
China Opens 2026 National E-Cigarette Standards Project for Public Submissions
The State Administration for Market Regulation (SAMR) and the State Tobacco Monopoly Administration (STMA) jointly announced the launch of the 2026 National Standardization Project for E-cigarettes. The initiative, coordinated by the National Technical Committee on Standardization of E-cigarettes, aims to enhance the industry’s regulatory framework through new standards on manufacturing, storage, distribution, and evaluation.
Nov.27 by 2FIRSTS.ai
Bangladesh Approves Philip Morris Factory for Nicotine Pouches, Sparks Controversy: Regulator Says It’s “Completely Legal”
Bangladesh Approves Philip Morris Factory for Nicotine Pouches, Sparks Controversy: Regulator Says It’s “Completely Legal”
Philip Morris Bangladesh Limited (PMBL) has received approval to invest USD 5.82 million in a nicotine pouch factory in Narayanganj. Regulators say the project is legal under existing laws, while health groups argue it breaches a 2016 Supreme Court order and poses youth addiction risks.
Nov.07 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai